Items tagged with Drug-resistant TB

TB Alliance and Liverpool School of Tropical Medicine collaborate to develop new TB therapies (post)

LIVERPOOL (September 19, 2018) – The Liverpool School of Tropical Medicine (LSTM) and TB Alliance are collaborating to investigate novel combination drug therapies that could help the fight against multidrug-resistant tuberculosis (MDR-TB), following an award of £1 million from the Medical Research Council.

Johnson & Johnson announces 10-year initiative to help end TB, the world’s #1 infectious killer (post)

J&J’s goal is to save an estimated 1.8 million lives and prevent 12 million new TB infections.

Unitaid extends key research grant as part of a strong counterattack on TB (post)

New York, 25 September 2018 – Unitaid is intensifying its commitment to fighting tuberculosis with a US$ 21 million investment in extending endTB, a global research project that is improving treatment regimens for patients with multidrug-resistant tuberculosis (MDR-TB).

Activists: Call on your countries to use bedaquiline-based regimens to treat TB (post)

The Global Coalition of TB Activists (GCTA), Treatment Action Group (TAG) and the DR-TB Scale-Up Treatment Action Team (DR-TB STAT) developed a letter template to help activists call for bedaquiline-based, injectable-free regimens for the treatment of drug-resistant TB in their countries.

Frequently Asked Questions on the WHO Rapid Communication: key changes to the treatment of multidrug- and rifampicin-resistant TB (post)

The World Health Organization (WHO) in collaboration with the Stop TB Partnership’s Global Drug Facility, the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States Agency for International Development have developed a set of frequently asked questions (and answers) in response to inquiries on upcoming WHO policy recommendations.

Fluoroquinolone and quinolone antibiotics: PRAC recommends new restrictions on use following review of disabling and potentially long-lasting side effects (post)

The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended restricting the use of fluoroquinolone and quinolone antibiotics (used by mouth, injection or inhalation) following a review of disabling and potentially long-lasting side effects reported with these medicines. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on fluoroquinolone and quinolone antibiotics in June 2018.

Bangladesh, USAID DR-TB treatment project shows impacts of community-based approach (post)

A project that shifted treatment for drug-resistant tuberculosis from overburdened Bangladesh hospitals to patients’ homes saw time between diagnosis and treatment initiation drop from more than three months to less than a week, reducing risks of the continued spread of the disease, a study reported in Global Health Science and Practice found. In the process, researchers found rates of treatment success climbed from 70 percent in 2011 to 76 percent in 2015, while death rates among patients treated for drug-resistant tuberculosis dropped from 14 percent to 9 percent.

Stories and videos on drug-resistant TB in India (post)

South Africa: Interim clinical guidance for the implementation of injectable-free regimens (post)

The Department of Health of South Africa released Interim clinical guidance for the implementation of injectable-free regimens for rifampicin-resistant tuberculosis in adults, adolescents and children.

Outbreak of multidrug-resistant TB in South Africa undetected by standard tests (post)

Due to inadequate lab tests, an outbreak of multidrug-resistant tuberculosis (MDR-TB) in South Africa has remained undetected for no less than five years. An international team of microbiologists led by Dr Emmanuel André (KU Leuven) and his South African colleague Ndivhuho Makhado present their findings in Lancet Infectious Diseases.